Rigel Pharms Inc Company Profile
✉ Email this page to a colleague
What is the competitive landscape for RIGEL PHARMS INC, and what generic alternatives to RIGEL PHARMS INC drugs are available?
RIGEL PHARMS INC has two approved drugs.
There are twenty-six US patents protecting RIGEL PHARMS INC drugs.
There are one hundred and eighty-six patent family members on RIGEL PHARMS INC drugs in fifty-two countries and sixteen supplementary protection certificates in fourteen countries.
Summary for Rigel Pharms Inc
International Patents: | 186 |
US Patents: | 26 |
Tradenames: | 2 |
Ingredients: | 2 |
NDAs: | 2 |
Drugs and US Patents for Rigel Pharms Inc
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Rigel Pharms Inc | TAVALISSE | fostamatinib disodium | TABLET;ORAL | 209299-002 | Apr 17, 2018 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Rigel Pharms Inc | REZLIDHIA | olutasidenib | CAPSULE;ORAL | 215814-001 | Dec 1, 2022 | RX | Yes | Yes | 11,498,913 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Rigel Pharms Inc | TAVALISSE | fostamatinib disodium | TABLET;ORAL | 209299-001 | Apr 17, 2018 | RX | Yes | No | 8,445,485 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Rigel Pharms Inc | TAVALISSE | fostamatinib disodium | TABLET;ORAL | 209299-001 | Apr 17, 2018 | RX | Yes | No | 8,652,492 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Rigel Pharms Inc Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
European Patent Office | 3447050 | ⤷ Try a Trial |
Denmark | 1856135 | ⤷ Try a Trial |
Lithuania | 2736487 | ⤷ Try a Trial |
Japan | 2017528489 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Rigel Pharms Inc Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1856135 | PA2020507,C1856135 | Lithuania | ⤷ Try a Trial | PRODUCT NAME: FOSTAMATINIBO DINATRIO HEKSAHIDRATAS; REGISTRATION NO/DATE: EU/1/19/1405 20200109 |
1856135 | C 2020 014 | Romania | ⤷ Try a Trial | PRODUCT NAME: SUPPLEMENTARY PROTECTION CERTIFICATE; NATIONAL AUTHORISATION NUMBER: C 2020 014; DATE OF NATIONAL AUTHORISATION: RO; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): 1856135; DATE OF FIRST AUTHORISATION IN EEA: 20220530 |
1856135 | PA2020507 | Lithuania | ⤷ Try a Trial | PRODUCT NAME: FOSTAMATINIBO DINATRIO HEKSAHIDRATAS; REGISTRATION NO/DATE: EU/1/19/1405 20200109 |
1856135 | 301039 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: FOSTAMATINIB OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT VAN FOSTAMATINIB, OF EEN HYDRAAT, SOLVAAT OF N-OXIDE VAN FOSTAMATINIB OF HET FARMACEUTISCH AANVAARDBARE ZOUT VAN FOSTAMATINIB, IN HET BIJZONDER DINATRIUMFOSTAMATINIB EVENTUEEL IN DE VORM VAN EEN HYDRAAT; REGISTRATION NO/DATE: EU/1/19/1405 20200113 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.